2024
Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology
Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B, He L, Sharma A, Ahuja N. Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology. Current Issues In Molecular Biology 2024, 46: 6533-6565. PMID: 39057032, PMCID: PMC11276574, DOI: 10.3390/cimb46070390.Peer-Reviewed Original ResearchCell-free DNA liquid biopsyCell-free DNALiquid biopsy technologiesLiquid biopsyBiopsy technologyEarly cancer detectionClinical applicationCfDNA-based liquid biopsyMonitoring residual diseaseEarly detection testsCancer detectionPotential of epigeneticsPersonalized cancer treatmentImprove cancer outcomesTissue of originFragmentation pattern analysisResidual diseaseDNA methylationMulti-cancer early detection testTreatment responseBiopsyCancer outcomesCancer preventionEpigeneticsPrecision oncologyProlonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection
Ying L, Ilagan-Ying Y, Kunstman J, Peters N, Almeida M, Blackburn H, Ferrucci L, Billingsley K, Khan S, Chhoda A, John N, Salem R, Sharma A, Ahuja N. Prolonged length of stay and omission of adjuvant therapy are associated with early mortality after pancreatic adenocarcinoma resection. Surgical Oncology Insight 2024, 1: 100007. DOI: 10.1016/j.soi.2024.100007.Peer-Reviewed Original ResearchFactors associated with early mortalityCases of pancreatic adenocarcinomaPancreatic adenocarcinoma resectionRisk of early mortalityLength of stayEarly mortalityAdjuvant chemotherapyPancreatic adenocarcinomaChemotherapy utilizationAdenocarcinoma resectionRisk factors associated with early mortalityOmission of adjuvant therapyNon-metastatic pancreatic adenocarcinomaMultivariate Cox regression modelAssociated with early mortalityPost-resection survivalIncreased risk of early mortalityParticipant Use FileProlonged hospital stayProlonged length of stayAdjuvant chemotherapy utilizationDecrease perioperative complicationsCox regression modelsNon-academic centersHospital risk factorsA phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.Peer-Reviewed Original ResearchRefractory to irinotecanArm ATAS-102DNA methyltransferase inhibitorArm BRates of progression free survivalB. Median overall survivalEvidence of target modulationMetastatic colorectal cancer patientsResistant to systemic therapyTreatment related adverse eventsProgression free survivalPhase II studyPhase II trialKaplan-Meier ratesRelated adverse eventsColorectal cancer patientsFree survivalOverall survivalSystemic therapyAdverse eventsIrinotecanRegorafenibCancer patientsGuadecitabineNeoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Johnson B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, Langbo W, Epstein J, Netto G, Baras A, Matoso A, McConkey D, Gupta A, Ahuja N, Ross A, Pierorazio P, Comperat E, Hoffman-Censits J, Singla N, Patel S, Kates M, Choi W, Bivalacqua T, Hahn N. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis. Bladder Cancer 2024, 10: 133-143. PMID: 39131872, PMCID: PMC11308648, DOI: 10.3233/blc-240008.Peer-Reviewed Original ResearchExpression of immune checkpointsClinical activityNeoadjuvant cisplatinImmune checkpointsT cellsIncreased expression of immune checkpointsTranscriptome RNA sequencingMuscle-invasive patientsPegfilgrastim 6 mgAggressive histologic subtypePathological complete responseUrothelial bladder cancerT cell genesBasal-squamousYpCR rateNeoadjuvant therapyComplete responseHistological subtypesSingle-institutionUrothelial cancerPrimary endpointUrothelial tumorsTumor biologyBladder cancerGrade 3
2023
Role of colectomy in the management of appendiceal tumors: a retrospective cohort study
Marks V, Kerekes D, Butensky S, Ahuja N, Johnson C, Turaga K, Khan S. Role of colectomy in the management of appendiceal tumors: a retrospective cohort study. BMC Gastroenterology 2023, 23: 398. PMID: 37978348, PMCID: PMC10655451, DOI: 10.1186/s12876-023-03019-4.Peer-Reviewed Original ResearchConceptsGoblet cell adenocarcinomaNon-mucinous adenocarcinomaRight hemicolectomyStage 2 diseaseNeuroendocrine neoplasmsTumor typesAppendiceal tumorsMucinous adenocarcinomaAppendiceal goblet cell adenocarcinomaRole of colectomyNational Cancer DatabasePostoperative hospital stayRetrospective cohort studyRisk-adjusted analysisRange of histologiesDifferent tumor typesConclusionsMost patientsHospital stayUnplanned readmissionCohort studySurgical treatmentHistologic typeSurgical outcomesCell adenocarcinomaCancer DatabaseThe Promise of Epigenetics Research in the Treatment of Appendiceal Neoplasms
Ladel L, Tan W, Jeyakanthan T, Sailo B, Sharma A, Ahuja N. The Promise of Epigenetics Research in the Treatment of Appendiceal Neoplasms. Cells 2023, 12: 1962. PMID: 37566041, PMCID: PMC10417136, DOI: 10.3390/cells12151962.Peer-Reviewed Original ResearchImpact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatients76 ROLE OF COLECTOMY FOR APPENDICEAL TUMORS
Marks V, Kerekes D, Ahuja N, Turaga K, Khan S. 76 ROLE OF COLECTOMY FOR APPENDICEAL TUMORS. Gastroenterology 2023, 164: s-1442. DOI: 10.1016/s0016-5085(23)04363-9.Peer-Reviewed Original ResearchTu1001 ASSESSMENT IN TIME TO TREATMENT INITIATION AND SURVIVAL IN COLORECTAL CANCER FROM 2004-2017: ANALYSIS OF THE NATIONAL CANCER DATABASE
Khatri R, Sharma A, John N, Ahuja N, Ehrlich A, Friedenberg F. Tu1001 ASSESSMENT IN TIME TO TREATMENT INITIATION AND SURVIVAL IN COLORECTAL CANCER FROM 2004-2017: ANALYSIS OF THE NATIONAL CANCER DATABASE. Gastroenterology 2023, 164: s-956. DOI: 10.1016/s0016-5085(23)03212-2.Peer-Reviewed Original ResearchA study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer
Baretti M, Murphy A, Zahurak M, Gianino N, Parkinson R, Walker R, Lopez-Vidal T, Zheng L, Rosner G, Ahuja N, Kurt S, Azad N. A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer. Clinical Epigenetics 2023, 15: 74. PMID: 37120591, PMCID: PMC10149019, DOI: 10.1186/s13148-023-01485-x.Peer-Reviewed Original ResearchConceptsColorectal cancer patientsAdvanced colorectal cancer patientsImmune checkpoint inhibitor therapyMedian progression-free survivalDurable partial responseHematological adverse eventsMMR-proficient tumorsCheckpoint inhibitor therapyAdvanced colorectal cancerProgression-free survivalImmune cell infiltrationHistone deacetylasesImmunologic shiftCheckpoint inhibitorsRECIST criteriaAdverse eventsCheckpoint therapyOverall survivalPartial responseInhibitor therapyMedian ageColorectal cancerFurther mechanistic investigationsCancer patientsCell infiltrationEarly Detection of Cancers in the Era of Precision Oncology
Tan W, Sharma A, Das P, Ahuja N. Early Detection of Cancers in the Era of Precision Oncology. Current Opinion In Oncology 2023, 35: 115-124. PMID: 36721896, DOI: 10.1097/cco.0000000000000931.Peer-Reviewed Original ResearchUtility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms
Chhoda A, Sharma A, Sailo B, Tang H, Ruzgar N, Tan W, Ying L, Khatri R, Narayanan A, Mane S, De Kumar B, Wood L, Iacobuzio-Donahue C, Wolfgang C, Kunstman J, Salem R, Farrell J, Ahuja N. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics 2023, 15: 28. PMID: 36803844, PMCID: PMC9942382, DOI: 10.1186/s13148-023-01429-5.Peer-Reviewed Original ResearchConceptsPapillary mucinous neoplasmMalignant risk stratificationCACNA1G geneRisk stratificationMucinous neoplasmsBiomarker panelBackgroundIntraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmEarly detectionPrevious case-control studyHigh-grade dysplasiaCase-control studyPancreatic cancer precursorsReceiver Operating Characteristic (ROC) curve analysisSignificant diagnostic challengeCross-sectional imagingCharacteristic curve analysisOperating Characteristic curve analysisG geneHigh diagnostic specificityPrior validation studiesSignificant procedural riskIPMN tissuesSurgical resectionAdvanced neoplasiaComparison of Male and Female Surgeons’ Experiences With Gender Across 5 Qualitative/Quantitative Domains
Zogg C, Kandi L, Thomas H, Siki M, Choi A, Guetter C, Smith C, Maduakolam E, Kondle S, Stein S, Shaughnessy E, Ahuja N. Comparison of Male and Female Surgeons’ Experiences With Gender Across 5 Qualitative/Quantitative Domains. JAMA Surgery 2023, 158: e226431. PMID: 36477515, PMCID: PMC9857060, DOI: 10.1001/jamasurg.2022.6431.Peer-Reviewed Original ResearchConceptsGender-based discriminationCareer aspirationsMentor-mentee relationshipGender-based harassmentImportance of genderMixed-methods surveyBody of literatureHonest discourseGender biasEducation initiativesFemale membersSelf-reported experiencesSelf-reported genderWorkforce diversityProfessional settingsGraduate degreeNegative aspectsAspirationGenderExperienceComparison of MaleMembersDiscourseHarassmentDiscrimination
2022
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence
Heumann T, Baretti M, Sugar E, Durham J, Linden S, Lopez-Vidal T, Leatherman J, Cope L, Sharma A, Weekes C, O’Dwyer P, Reiss K, Monga D, Ahuja N, Azad N. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Clinical Epigenetics 2022, 14: 166. PMID: 36463226, PMCID: PMC9719150, DOI: 10.1186/s13148-022-01367-8.Peer-Reviewed Original ResearchConceptsResectable pancreatic ductal adenocarcinomaCC-486OBS patientsMetastatic settingAdjuvant therapyTreatment-related grade 3Randomized phase II studyMedian age 66Next-line therapyResultsForty-nine patientsMedian treatment durationPhase II studyEvidence of diseaseHigh-risk featuresPhase II trialProgression-free survivalStandard adjuvant therapyPancreatic ductal adenocarcinomaCancer recursEvaluable patientsMedian OSMedian PFSOral azacitidineR1 resectionSubsequent chemotherapyBile acid distributions, sex-specificity, and prognosis in colorectal cancer
Cai Y, Shen X, Lu L, Yan H, Huang H, Gaule P, Muca E, Theriot CM, Rattray Z, Rattray NJW, Lu J, Ahuja N, Zhang Y, Paty PB, Khan SA, Johnson CH. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. Biology Of Sex Differences 2022, 13: 61. PMID: 36274154, PMCID: PMC9590160, DOI: 10.1186/s13293-022-00473-9.Peer-Reviewed Original ResearchConceptsLeft-sided colon tumorsRight-sided colon tumorsColon cancer patientsColorectal cancerTumor locationBile acidsColon tumorsCancer patientsQuantitative immunofluorescencePrimary tumor locationImmune regulatory cellsRecurrence-free survivalBile acid metabolismSecondary bile acidsBile acid distributionBile acid analysisBackgroundBile acidsOverall survivalRegulatory cellsCRC patientsMale patientsPatient sexImmune cellsPatient prognosisImmune responseHow Male and Female Surgeons’ Experiences with Gender in Surgery Compare: National Concurrent Mixed-Methods Survey of Fellows of the American College of Surgeons
Zogg C, Kandi L, Thomas H, Siki M, Ahuja N. How Male and Female Surgeons’ Experiences with Gender in Surgery Compare: National Concurrent Mixed-Methods Survey of Fellows of the American College of Surgeons. Journal Of The American College Of Surgeons 2022, 235: s221-s222. DOI: 10.1097/01.xcs.0000894740.81658.e5.Peer-Reviewed Original ResearchBenefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.Peer-Reviewed Original ResearchConceptsDisease-specific mortalityAdvanced neoplasiaBD-IPMNsExtended surveillancePooled incidenceWorrisome featuresSystematic reviewIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmHigh-quality studiesRandom-effects modelWarrants further investigationWeb of ScienceNeoplasia incidenceWarrants further explorationSurvival benefitCochrane LibraryMucinous neoplasmsPancreatic cancerPancreatic cystsSurveillance periodEligible studiesOvid MEDLINELower incidenceMo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS
Chhoda A, Sharma A, Tang H, Tan W, Sailo B, Peters N, Ying L, Ruzgar N, Kunstman J, Salem R, Farrell J, Ahuja N. Mo1131: HIGHLY SPECIFIC PROMOTER METHYLATION MARKERS FOR MALIGANT STRATIFICATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. Gastroenterology 2022, 162: s-708. DOI: 10.1016/s0016-5085(22)61664-0.Peer-Reviewed Original ResearchTu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS
Singh S, Chhoda A, Vodusek Z, Khatri R, Gunderson C, McCarty T, Sharma P, Grimshaw A, Kunstman J, Sharma A, Ahuja N, Gonda T, Farrell J. Tu1185: DOES CURRENT EVIDENCE SUPPORT CYST GROWTH RATE AS A WORRISOME FEATURE? A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2022, 162: s-907. DOI: 10.1016/s0016-5085(22)62148-6.Peer-Reviewed Original Research1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE
Khatri R, Chhoda A, Sharma A, Farrell J, Ahuja N, Ehrlich A, Friedenberg F. 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE. Gastroenterology 2022, 162: s-270-s-271. DOI: 10.1016/s0016-5085(22)60641-3.Peer-Reviewed Original Research